|
rs523349
|
|
|
0.080 |
GeneticVariation |
BEFREE |
<i>SRD5A2</i> rs523349 (V89L) polymorphism showed no significant role in BPH occurrence in total analysis, but its reducing and increasing effects on the disease risk were reflected in Caucasian and other-ethnicity subgroups, respectively, after stratification analysis by ethnicity.
|
28955247 |
2017 |
|
rs523349
|
|
|
0.080 |
GeneticVariation |
BEFREE |
For the V89L polymorphism there were no significant differences in genotype frequencies in patients with prostate cancer and controls (p = 0.071) or in patients with BPH and male controls (p = 0.219).
|
12771801 |
2003 |
|
rs523349
|
|
|
0.080 |
GeneticVariation |
BEFREE |
The enzyme is a target in pharmacological treatment of benign prostatic hyperplasia using specific inhibitors such as finasteride.Makridakis et al. have characterized the V89L and A49T polymorphisms in recombinant expression systems.
|
12042668 |
2002 |
|
rs523349
|
|
|
0.080 |
GeneticVariation |
BEFREE |
Although V89L was nonsignificantly associated with BPH in overall population, BPH risk increased significantly with the number of L alleles in Hispanics (P for trend=0.03).
|
16018939 |
2005 |
|
rs523349
|
|
|
0.080 |
GeneticVariation |
BEFREE |
In men with a clinical diagnosis of benign prostatic hyperplasia (BPH), polytomous logistic regression analysis was conducted to evaluate associations between two silent polymorphisms in SRD5A1 (codon positions 30 and 116), two polymorphisms in SRD5A2 (Val89Leu substitution and C to T transition in intron 1), a trinucleotide (CAG)n repeat in androgen receptor (AR), and an Arg492Cys substitution in ADRA1A and clinical parameters that characterize severity of BPH.
|
15136785 |
2004 |
|
rs523349
|
|
|
0.080 |
GeneticVariation |
BEFREE |
The SRD5A2 polymorphisms A49T, V89L and R227Q, the androgen receptor CAG and GGN repeats and sex hormone status was investigated in men with prostate cancer (CaP) (n=89), benign prostate hyperplasia (n=45) and healthy military conscripts (n=223).
|
16039774 |
2005 |
|
rs523349
|
|
|
0.080 |
GeneticVariation |
BEFREE |
The aim of our study was to determine the frequency of the <i>SRD5A1</i> (rs6884552, rs3797177) and <i>SRD5A2</i> (rs523349, rs12470143) genes' polymorphisms, and to assess the relationships between the genotypes of the tested mutations, and the levels of biochemical and hormonal parameters in patients with BPH.
|
29084161 |
2017 |
|
rs523349
|
|
|
0.080 |
GeneticVariation |
BEFREE |
CYP19 1531 C>T, SRD5A2 gene V89L, CYP17 gene -34 T/C, PSA-158 (G/A) regions were evaluated for the association between polymorphisms and benign prostatic hyperplasia and prostate cancer in study population.
|
26214411 |
2015 |
|
rs9282858
|
|
|
0.060 |
GeneticVariation |
BEFREE |
Prostate cancer and BPH were not associated with the alanine-49 to threonine single nucleotide polymorphism and the (TA)n repeat.
|
16018939 |
2005 |
|
rs9282858
|
|
|
0.060 |
GeneticVariation |
BEFREE |
The SRD5A2 polymorphisms A49T, V89L and R227Q, the androgen receptor CAG and GGN repeats and sex hormone status was investigated in men with prostate cancer (CaP) (n=89), benign prostate hyperplasia (n=45) and healthy military conscripts (n=223).
|
16039774 |
2005 |
|
rs9282858
|
|
|
0.060 |
GeneticVariation |
BEFREE |
The enzyme is a target in pharmacological treatment of benign prostatic hyperplasia using specific inhibitors such as finasteride.Makridakis et al. have characterized the V89L and A49T polymorphisms in recombinant expression systems.
|
12042668 |
2002 |
|
rs9282858
|
|
|
0.060 |
GeneticVariation |
BEFREE |
The A49T and TA repeat polymorphisms were not associated with BPH.
|
15389785 |
2005 |
|
rs9282858
|
|
|
0.060 |
GeneticVariation |
BEFREE |
We found statistically significant relationship between the SRD5A2 gene Ala49Thr (OR=2.3; CI 95%, 1.04-5.1; p=0.01<0.05) , but not the other polymorphisms, and B</span>PH.
|
21627373 |
2011 |
|
rs9282858
|
|
|
0.060 |
GeneticVariation |
BEFREE |
<b>Results:</b><i>SRD5A2</i> rs9282858 (A49T) polymorphism showed a significant correlation with increased B</span>PH susceptibility under allele T vs.allele A genetic model (OR = 2.51, 95% CI = 1.29-4.88) in total analysis, and stratification analysis by ethnicity also revealed a similar association in Caucasian group under the same contrast.
|
28955247 |
2017 |
|
rs149709822
|
|
|
0.020 |
GeneticVariation |
BEFREE |
The A49T and TA repeat polymorphisms were not associated with BPH.
|
15389785 |
2005 |
|
rs149709822
|
|
|
0.020 |
GeneticVariation |
BEFREE |
The enzyme is a target in pharmacological treatment of benign prostatic hyperplasia using specific inhibitors such as finasteride.Makridakis et al. have characterized the V89L and A49T polymorphisms in recombinant expression systems.
|
12042668 |
2002 |
|
rs1799864
|
|
|
0.020 |
GeneticVariation |
BEFREE |
In the present study, the aim was to evaluate the association of three polymorphisms in chemokine genes, namely C‑C motif chemokine ligand (CCL)2 rs1024611, CC chemokine receptor 2 (CCR2) rs1799864 and CCL5 rs2107538, with BPH risk.
|
30816510 |
2019 |
|
rs1799864
|
|
|
0.020 |
GeneticVariation |
BEFREE |
The impact of two chemokine receptor gene polymorphisms, CCR2-64I (rs1799864) and CCR5-Δ32 (rs333), was evaluated in BPH and PCa.
|
23632061 |
2013 |
|
rs1799983
|
|
|
0.020 |
GeneticVariation |
BEFREE |
The endothelial nitric oxide synthase Glu-298-Asp polymorphism and its mRNA expression in the peripheral blood of patients with prostate cancer and benign prostatic hyperplasia.
|
16458450 |
2006 |
|
rs1799983
|
|
|
0.020 |
GeneticVariation |
BEFREE |
The association of endothelial nitric oxide synthase (eNOS) G894T gene polymorphism with responsiveness to a selective α1 -blocker in men with benign prostatic hyperplasia related lower urinary tract symptoms.
|
26940040 |
2016 |
|
rs10035432
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We found an inverse association between SNP rs10035432 and BPH under the log-additive (p=0.007) model.
|
26124326 |
2015 |
|
rs1024611
|
|
|
0.010 |
GeneticVariation |
BEFREE |
No association was observed between the CCL2 rs1024611 polymorphism and BPH.
|
30816510 |
2019 |
|
rs103294
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Association between rs103294, BPH risk and clinicopathological traits were tested with adjustment for age. rs103294 was significantly associated with BPH risk with a p-value of 0.0067.
|
23615473 |
2013 |
|
rs1034866440
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The SRD5A2 polymorphisms A49T, V89L and R227Q, the androgen receptor CAG and GGN repeats and sex hormone status was investigated in men with prostate cancer (CaP) (n=89), benign prostate hyperplasia (n=45) and healthy military conscripts (n=223).
|
16039774 |
2005 |
|
rs1045531
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Statistically significant differences in the distribution of the rs1045531 genotypes and alleles were found between prostate cancer and benign prostatic hyperplasia in patients undergoing prostate biopsy ( P = .035 and .046, respectively).
|
29332451 |
2017 |